Contents
Copay foundation batch file kickbacks involve coordinating charitable funding and patient applications so a drugmaker’s money reaches patients taking its own drug. A hub counts patients waiting for assistance, the manufacturer learns how much funding they need, and a batch of applications reaches the foundation when its fund reopens. If you work in benefits investigation, patient access or a specialty pharmacy, you may know who requested that count and who told the team when to send the file. Those decisions connect the donation to the prescriptions it supports.
Moving a patient from a manufacturer’s free-drug program to foundation assistance changes who pays for the medicine. Free-drug assistance supplies the product without generating a Medicare claim. When a foundation covers the patient’s copay instead, Medicare pays the remaining covered cost and the manufacturer earns revenue.
That difference explains why a company might spend more on foundation contributions than it would cost to supply the drug free. The government alleged exactly that in Amgen’s Sensipar arrangement. In that alleged arrangement, the contribution bought access to a paying prescription.
Medicare Part B and Part D patients often bear part of a drug’s cost through a copayment, coinsurance or deductible. The Justice Department explains in its account of the Dompé settlement that Congress included this cost sharing partly to check drug prices. A patient can receive help while the arrangement also removes a constraint on what the manufacturer charges. Taxpayers pay the larger health care bill.
For a patient assistance employee, donation timing and batch files can connect decisions made in different organizations. The useful evidence includes what the foundation told the hub, what the hub told the drugmaker, and what happened to the applications afterward.
The Advanced Care Scripts case shows how those records fit together:
The connection includes who requested the information and how it was used to size a payment. That is where an employee’s knowledge adds something the timestamps cannot say.
Busting Bad Medicine: a Call to Action Addressing Healthcare, Fraud, Waste, and Abuse, published in the Journal of AHIMA in 2017, emphasizes that investigators need witnesses who can explain the conduct as well as documentation. In a copay case, the employee who explained a waiting-patient report to the funding team may understand why the next donation took the amount it did. We connect that knowledge to the applications and the payment trail.
Pharmaceutical kickbacks can work through an intermediary that pays patients’ costs to induce purchases of the manufacturer’s drugs. In the batch-file cases, the foundation supplies the copay assistance and the hub connects the patients, the funding information and the applications.
The Anti-Kickback Statute bars drugmakers from paying Medicare patients, directly or through others, to buy their drugs. Under the False Claims Act, a manufacturer can be responsible for the resulting false claims even when a pharmacy sends the bill.
Advanced Care Scripts provided benefits investigation services for Teva. In its August 2020 settlement, ACS acknowledged relaying data from Chronic Disease Fund and The Assistance Fund so Teva could match its contributions to spending on Copaxone patients.
When the foundations lacked funding and stopped accepting applications, ACS regularly told Teva how many of its Medicare Part D patients had Copaxone prescriptions, met the foundations’ criteria and were waiting for copay coverage. At least one ACS employee understood that Teva would use those counts to help determine its next payment. Teva sometimes gave ACS advance notice of its contributions.
Once ACS learned that a fund had reopened, it promptly sent a batch file consisting almost entirely of Copaxone patients’ applications. ACS often then received notice that most or all of those applications had been approved.
A copay charity fund opened after a donation, batch applications arrived, and approvals followed. The detail that gives this sequence its force is the information moving ahead of the money: the drugmaker received the waiting count, and the hub sometimes received advance notice of the payment. ACS acknowledged those operational facts.
ACS agreed to pay $3.5 million for its role. Teva later agreed to a separate $425 million copay settlement in October 2024 over allegations that it used the foundations and a specialty pharmacy to direct assistance to Copaxone patients.
Biogen allegedly coordinated with ACS to time foundation payments with the transfer of financially needy patients from free-drug assistance. The December 2020 resolution concerned Avonex and Tysabri copays funded through Chronic Disease Fund and The Assistance Fund.
In the government’s account, patients who had received free medicine moved into Medicare-paid prescriptions. The alleged timing connects the free-drug roster and the donation forecast.
Novartis allegedly arranged for a foundation’s multiple sclerosis fund to open at 6:00 p.m. on a Friday while its contractor had personnel working overtime to submit applications. The government’s account explains the population behind that schedule: in October 2012, the contractor managing the Gilenya free-drug program told Novartis that more than 300 patients receiving free medicine would become eligible for Medicare in 2013.
The alleged coordination reached the people doing the application work: the contractor staffed the opening Novartis had arranged. The schedule served patients the company already knew were coming.
At a copay foundation with no waiting list, manufacturer patients’ access to assistance can turn on when a fund reopens. The Sanofi allegations describe The Assistance Fund’s multiple sclerosis fund repeatedly running out of money and closing to new patients. It kept no waiting list of patients who applied while the fund was closed.
The government also alleged that the foundation raised its maximum grant to $20,000 per patient specifically to accommodate Lemtrada patients.
Read beside the ACS sequence, the absence of a waiting list explains the value of advance information. A hub ready at reopening could put its patients in front of newly available funding.
A whistleblower’s complaint against Incyte alleged that the company moved some Jakafi patients who might have qualified for free medicine toward foundations covering Medicare copays. The complaint connects that move directly to the resulting claims:
In order to generate revenue, and instead of giving away Jakafi for free to Medicare patients who may have met the financial qualifications of a free drug program, Incyte worked to transition some portion of these patients to certain foundations which covered the patients’ Medicare copays and caused Medicare claims to result from the filling of the patients’ Jakafi prescriptions.
The complaint further alleged that Incyte received foundation data confirming payment of Jakafi patients’ Medicare copays. The alleged information flow ran in both directions: money toward the foundation, confirmation of support for the manufacturer’s product back toward the company.
The government’s amended complaint against Regeneron alleged that employees asked Chronic Disease Fund how much it needed to cover Eylea patients’ copays, then calculated the Medicare revenue those patients would generate. According to the complaint, they calculated a return of over 400% on the company’s payments to the foundation. The charitable donation was being priced like an investment.
The complaint alleged that Regeneron paid exactly what the foundation said it needed for Eylea patients’ Medicare expenses. It also alleged that the company selected a higher launch price knowing it could cover the increased patient burden by paying more to the foundation. The forecast connected the contribution, the product and the expected revenue. That is why a donation budget can matter as much as an application file.
Dompé admitted holding some foundation funding in reserve so it could allocate money during the year to foundations running low. Its September 2026 settlement concerned Oxervate copays. The admissions show an annual budget that could change with the number of patients waiting for help.
Around the drug’s launch, employees expressed reservations about launching before paying a patient assistance foundation. Two foundations opened funds after conversations with company employees. Dompé contributed to them and sometimes increased funding during the year.
The settlement agreement linked by the Justice Department records a more specific exchange. A Market Access employee and a consultant responsible for foundation relationships compared information from a specialty pharmacy and a foundation to determine how many Oxervate patients were pending there. The consultant used foundation and pharmacy data when recommending contribution budgets. A compliance consultant also advised employees against reverse-engineering foundation activity to inform those decisions.
Dompé also admitted that sales staff sought information from patient access staff about particular patients’ foundation coverage despite compliance guidance. The data had reached people making commercial and funding decisions.
A foundation can favor a manufacturer’s patients through its eligibility rules before any batch arrives. The covered drugs can matter as much as the opening schedule.
In its account of the Chronic Disease Fund resolution, the government alleged that Novartis financed a disease fund that covered Afinitor but excluded Sutent, the other approved drug. The disease label sounded broader than the assistance it offered.
The Department of Health and Human Services’ Office of Inspector General calls for assistance independent of manufacturer control and product preferences, awarded on consistent financial-need criteria. Its patient-assistance guidance also addresses data that lets a manufacturer match donations to subsidized prescriptions. Narrow categories based on symptoms, severity or how a drug is administered can channel assistance toward particular products.
Patient Access Network Foundation entered its own settlement and integrity agreement over alleged manufacturer-specific assistance arrangements. HHS-OIG also explained that an advisory opinion issued to a charity does not protect a donor’s separate conduct. We examine both sides of the healthcare payment: the fund’s rules and the donor’s involvement.
If you worked with waiting-patient counts, donation forecasts or foundation applications, tell our whistleblower experts who connected the funding to the patients. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We work beside you to build your strongest pharmaceutical copay whistleblower case and bring in pharmaceutical whistleblower lawyers who know foundation kickbacks and the False Claims Act.